Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $67,425 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $67,425 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $167,768 | $235,158 | $172,734 | $175,601 |
| G&A Expenses | $87,115 | $59,398 | $54,553 | $40,941 |
| SG&A Expenses | $87,115 | $59,398 | $54,553 | $40,941 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3,736 | $4,953 | $0 | $0 |
| Operating Expenses | $258,619 | $299,509 | $227,287 | $216,542 |
| Operating Income | -$191,194 | -$299,509 | -$227,287 | -$216,542 |
| % Margin | -283.6% | – | – | – |
| Other Income/Exp. Net | $25,504 | $6,603 | -$10,295 | $50,152 |
| Pre-Tax Income | -$165,690 | -$292,906 | -$237,582 | -$166,390 |
| Tax Expense | $177 | -$601 | -$469 | -$297 |
| Net Income | -$165,839 | -$292,191 | -$236,806 | -$158,725 |
| % Margin | -246% | – | – | – |
| EPS | -2.33 | -4.47 | -4.48 | -3.72 |
| % Growth | 47.9% | 0.2% | -20.4% | – |
| EPS Diluted | -2.33 | -4.47 | -4.48 | -3.72 |
| Weighted Avg Shares Out | 71,080 | 65,409 | 52,857 | 42,688 |
| Weighted Avg Shares Out Dil | 71,080 | 65,409 | 52,857 | 42,688 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $0 |
| Interest Expense | $0 | $0 | $2,575 | $0 |
| Depreciation & Amortization | $1,289 | $1,389 | $1,426 | $544 |
| EBITDA | -$186,169 | -$247,599 | -$225,861 | -$207,198 |
| % Margin | -276.1% | – | – | – |